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A pilot study of the in vitro antimicrobial
activity and in vivo residual activity of
chlorhexidine and acetic acid/boric acid
impregnated cleansing wipes
Rebecca Rafferty1, Victoria H. Robinson2* , Jennifer Harris1, Sally A. Argyle1 and Tim J. Nuttall1
Abstract
Background: Topical antimicrobials are recommended for first line treatment of surface and superficial infections in
dogs. This is especially important given the increasing prevalence of antimicrobial resistant infections. Antimicrobial
wipes have become popular, but there are a lack of controlled studies assessing their in vitro antimicrobial and
in vivo residual activity. We aimed to assess the antimicrobial efficacy of two commercial antimicrobial wipes
against frequently isolated pathogens.
Ten clinical and one reference isolate each of meticillin-susceptible Staphylococcus pseudintermedius (MSSP),
meticillin-resistant S. pseudintermedius (MRSP), Escherichia coli (EC), extended spectrum beta-lactamase (ESBL)
producing E. coli (ESBL-EC), Pseudomonas aeruginosa (PA) and Malassezia pachydermatis (MP) were tested
using a modified Kirby-Bauer technique. Each isolate was tested against 6 mm discs of chlorhexidine (CHX)
and acetic acid/boric acid (AABA) wipes, and positive and negative controls either overnight (bacteria) or
for 3 days (Malassezia).
Healthy dogs were treated with the wipes and distilled water on a randomised flank (n = 5 each). Hair
samples (1 cm; 0.1 g) taken at days 0, 1 and 3 were inoculated with an isolate of each organism. Zones of
inhibition (ZI) were measured.
Results: All isolates produced confluent growth with AABA and control wipes, except for the cleansing
wipes and MP (median ZI 12 mm; 95% CI 8.2–15.8). The median (95% CI) CHX wipe ZIs (mm) were: MP 48.0
(47.0–49.0), MSSP 15.6 (14.2–17.0), MRSP 14.0 (13.6–14.4), EC 13.6 (12.0–15.2) and ESBL-EC 10.0 (9.4–10.6). PA
showed confluent growth. The differences between the bacterial isolates was significant (Kruskal-Wallis p <
0.0001; post-tests MSSP = MRSP = EC > EBSL-EC > PA). Confluent growth was visible with all the hair samples.
Conclusion: CHX but not AABA showed in vitro efficacy against MSSP, MRSP, EC and MP. ESBL-EC were
less susceptible and there was no activity against PA. There was no residual activity on hair. Additional
studies are required to determine efficacy of these products in clinically affected patients.
Keywords: Topical, Antimicrobial wipe, Chlorhexidine, Acetic acid, Boric acid, Microbial infection, Cutaneous,
Dog
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Background
Antimicrobial resistance (AMR) is a growing concern in
human and veterinary healthcare. Treatment with sys-
temic antibiotics, particularly broad-spectrum agents, is
an important driver for the selection and dissemination
of AMR. There is therefore renewed interest in using
effective antiseptics to reduce systemic antibiotic use.
For example, topical antiseptic therapy, particularly
with chlorhexidine shampoos, is recommended as first
line therapy for surface and superficial pyodermas in
dogs [1, 2].
Antiseptic wipes are popular for their ease of use com-
pared to shampoos [3], but it is important to know that
the products are effective. Chlorhexidine (CHX) contain-
ing wipes (CLX® wipes containing chlorhexidine, climba-
zole and trisEDTA; ICF, Cremona, Italy) and acetic acid/
boric acid (AABA) wipes (Malacetic® wipes containing
acetic and boric acid; Dechra® Veterinary Products,
Shrewsbury, UK) are both marketed as antiseptic, anti-
bacterial and/or antifungal cleansing wipes. One study
evaluated the in vivo and in vitro activity of CHX wipes
against Malassezia pachydermatis in an experimental
model with 5 shar pei dogs [4]. Applying the wipes 1 or
2 times daily to the skin for 30 s significantly reduced
Malassezia pachydermatis counts on contact plates. In
vitro assays using the wipe solution demonstrated
complete kill in 6 isolates after 15 min contact time.
However, antibacterial efficacy was not assessed and
there were no control groups in the study. To our know-
ledge, there are no other peer-reviewed publication on
the efficacy of these antiseptic wipes.
The aim of this pilot study was to assess the in vitro
antimicrobial efficacy and residual in vivo antimicrobial
activity of these wipes against meticillin-susceptible
Staphylococcus pseudintermedius (MSSP), meticillin-
resistant S. pseudintermedius (MRSP), Escherichia coli
(EC), extended spectrum beta-lactamase (ESBL) produ-
cing E. coli (ESBL-EC), Pseudomonas aeruginosa (PA)
and Malassezia pachydermatis (MP) isolates. S. pseu-
dintermedius and MP are commensals of canine skin
and are frequently associated with microbial infections.
PA, EC and ESBL-EC are less commonly isolated from
cutaneous infections but they are important causes of
ear, wound and surgical site infections [5–10].
Results
The positive control antimicrobial discs produced the
expected ZIs (zones of inhibition) for susceptibility based
on the breakpoints observed in their clinical identification
and antimicrobial susceptibility testing. Colony morph-
ology and cytology was consistent with pure cultures.
There was no growth on any of the negative control plates
(i.e. without an inoculum).
Antimicrobial activity in vitro
The CHX wipes produced significantly greater ZIs than
the AABA wipes, paper towel or cleansing wipes for the
MSSP, MRSP, EC, ESBL-EC and MP isolates (all p <
0.0001; see Table 1) but there was no difference between
the AABA wipes, paper towel and cleansing wipes where
most isolates achieved confluent growth (p = 0.05 to 1.0).
All of the PA isolates achieved confluent growth with
the CHX and AABA wipes, paper towel and cleansing
wipes. There was a significant difference between the
ZIs for the CHX wipes among the different bacteria with
MSSP =MRSP = EC > ESBL-EC > PA (p < 0.0001). The
ZIs for the reference isolates all fell within the ranges
seen with the clinical isolates.
Residual antimicrobial activity in vivo
All the bacterial and Malassezia isolates achieved conflu-
ent growth around all the hair samples at days 0, 1 and 3.
Discussion
This study shows that the CHX wipes show in vitro effi-
cacy against a range of pathogenic isolates relevant to skin
and wound infections in animals, including MSSP, MRSP,
EC, ESBL-EC and MP. The small differences between ZIs
for MSSP, MRSP and EC were non-significant, but the
Table 1 Zones of inhibition (ZIs) of tested wipes. In vitro antimicrobial efficacy showing median (95% CI) of the zones of inhibition
(ZIs) (mm; Con = confluent growth) of the chlorhexidine (CHX) wipes, acetic acid/boric acid (AABA) wipes, paper towel and
cleansing wipes (MSSP =meticillin-susceptible S. pseudintermedius; MRSP =meticillin-resistant S. pseudintermedius; EC = E. coli; ESBL-
EC = extended spectrum beta-lactamase producing E. coli; PA = Pseudomonas aeruginosa; MP =Malassezia pachydermatis; n = 11
[10 clinical isolates and 1 Public Health England National Collection of Types Culture (NCTC) and Public Health England National
Collection of Pathogenic Fungi (NCPF reference isolates])
MP MSSP MRSP EC ESBL-EC PA
CHX wipes 48.0
(47.0-49.0
15.6
(14.2-17.0)
14.0
(13.6-14.4)
13.6
(12.0-15.2)
10.0
(9.4-10.6)
Con
AABA wipes Con Con Con Con Con Con
Cleansing wipes 12
(8.2-15.8)
Con Con Con Con Con
Paper towel Con Con Con Con Con Con
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ESBL-EC showed significantly smaller ZIs and all the PA
isolates achieved confluent growth. In contrast, all of the
isolates achieved confluent growth when incubated with
the AABA impregnated wipes. Neither wipe demonstrated
any persistent activity on hair samples after thorough
application in five dogs.
Chlorhexidine is an effective broad-spectrum anti-
microbial [11–14]. Chlorhexidine containing shampoos,
ear cleaners and sprays have shown in vivo and in vitro
efficacy against a range of organisms including Pseudo-
monas [15–21]. The reason for the poor efficacy against
PA (and to some extent ESBL-EC) in this study is un-
known. Resistance to chlorhexidine has been associated
with antibiotic resistance, which may be relevant to the
multi-drug resistance seen in the PA and ESBL-EC iso-
lates used in this study [22]. Kandry and colleagues
showed that 22 out 36 MDR PA isolates carried class I
integrons with reduced susceptibility to biocides includ-
ing chlorhexidine. Furthermore, quaternary ammonium
compound resistance E (qacE) genes, which are associ-
ated with chlorhexidine resistance, were identified in 11
isolates [22]. Nevertheless, while treatment failures are
seen, these have not been proven to be associated with
resistance to chlorhexidine in staphylococci and other
bacteria in veterinary medicine. The relationship be-
tween resistance genes to clinical failure or success is
therefore unclear.
Uri and others (2016) reported that the minimal in-
hibitory concentration (MIC) of MDR (multiple drug re-
sistant) PA was 0.94 g/L compared to the recommended
concentration of 0.5 g/L. [23] The wipes in our study
contain 0.3% (3 g/L) chlorhexidine, which is lower than
that in many topical products (typically 2–4%; 20-40 g/
L). Nevertheless, in vitro inhibition has been demon-
strated with a 0.15% chlorhexidine ear cleaner, and
chlorhexidine has MIC and minimal bactericidal concen-
trations (MBCs) of 0.6–10 mg/L against the ESBL-EC
and 5–10mg/L against the PA isolates used in this study
(data submitted for publication). MBCs of chlorhexidine
to PA in previous veterinary studies have been found to
be between 5 and 28mg/ml [24, 25] and MIC in human
studies of 4mg/ml [26]. which compares favourably to our
submitted study. MICs for chlorhexidine against ESBL-EC
in human clinical isolates was determined as < 1-2mg/L
[26, 27] and in avian isolates as 0.5-1mg/L. [27] MBCs of
ESBL-EC were 7.32mg/L (3min incubation) to 1.83mg/L
(10min incubation) with a 4% chlorhexidine product, and
468.75mg/L (3 and 10min incubations) with a 3% chlor-
hexidine/0.5% climbazole product [23]. These additional
studies have determined MIC/MBC comparable to the
our submitted study.
Nonetheless, it is difficult to extrapolate the effective
in vitro and in vivo concentration that bacteria would be
exposed to using chlorhexidine-impregnated wipes. It is
unknown how diffusion of the chlorhexidine, acetic acid/
boric acid, and other ingredients into the surrounding
MH and SD agar affected the concentration that the or-
ganisms were exposed to. However, studies of the anti-
microbial efficacy of products with these ingredients in
agar well diffusion [28, 29] and agar plated hair models
[30, 31] suggest that they freely diffuse into the media.
The CHX wipes also contained trisEDTA, zinc gluco-
nate, climbazole and a range of other ingredients
(Table 2). Their antimicrobial efficacy and/or effect on
the efficacy of the chlorhexidine is unknown. TrisEDTA
exhibits very little antimicrobial efficacy by itself, al-
though it can potentiate the activity of chlorhexidine
with 21% of isolates [13] particularly at high concentra-
tions (at least 25–50 g/L of a 4.2:1 combination Tri-
sEDTA:chlorhexidine; data submitted for publication). It
is unknown whether climbazole or chlorhexidine show
additive or synergistic activity against MP, where the ZIs
around the CHX disc were greater than the control anti-
fungal disc. Fractional inhibition indices studies could be
performed in future to determine if there is an additive
or synergistic interaction between these compounds. Mi-
conazole exhibits additive [13, 14] and synergistic [14]
activity with chlorhexidine against some MSSP and
MRSP isolates but is not known if this occurs with
climbazole.
Table 2 Composition of the antimicrobial and control wipes
according to the manufacturer’s data
Chlorhexidine (CHX)
wipes (CLX®wipes, ICF®,
Cremona, Italy)
0.3% Chlorhexidine
0.5% Climbazole
1% Zinc gluconate
TrisEDTA
Glycerin
Non-ionic surfactant
Benzyl alcohol
Propylene glycol
Perfume
Demineralized water
Acetic acid/boric acid
(AABA) wipes (Malacetic®
wipes (Dechra® Veterinary
Products, Shrewsbury, UK)
2% Acetic acid
2% Boric acid
Propylene glycol
Glycerin
Fragrance
Simple® Kind to Skin Facial
Cleansing Wipes (Unilever,
Leatherhead, UK)
Aqua
Benzoic acid
Cetearyl isononanoate
Ceteareth-12
Ceteareth-20
Cetearyl alcohol
Citric acid
Dehydroacetic acid
Disodium EDTA
Glycerin
Glyceryl stearate
Panthenol
Pantolactone
Phenoxyethanol
Sodium citrate
Tocopheryl acetate
Rafferty et al. BMC Veterinary Research          (2019) 15:382 Page 3 of 7
No antimicrobial activity was seen with the AABA
wipes. Similar findings have been reported for 2% acetic
acid/2% boric acid ear cleaners and shampoos in broth
dilution studies [20, 21].Several human studies have
looked at the antibacterial activity of acetic acid. MICs
for PA and EC varied from 1.25–3.1 mg/ml [32–34] and
3.1 mg/ml for ESBL-EC [34]. This suggests that the anti-
microbial activity of acetic acid varies within and be-
tween studies. There are few studies assessing boric acid,
but reported MICs are 7.6 mg/ml against single isolates
of EC and PA [35] and 0.385–0.77mg/ml for two PA
isolates [36] thus showing variation. Therefore, although
acetic acid and boric acid are antimicrobial, dilution
and/or interaction with other ingredients in the wipes
may reduce the antimicrobial efficacy.
Our study also shows that there was no residual
in vitro activity from hairs treated with these antiseptic
wipes against the tested isolates. Only one isolate of each
organism was tested, but we selected the isolate with the
largest ZI to the CHX wipes to best show antimicrobial
activity. The same isolates were used for AABA wipes as
the earlier confluent growth prevented selection of an
isolate in the same way. It is possible that there may
have been some short-term activity as the first samples
were collected 24 h after application. This study could
have been improved by collecting a hair sample at
shorter time intervals such as 30mins. The authors are
unaware of any short term clinical studies using this
product. However, studies with identical methodology
have shown that canine hairs show in vitro antimicrobial
activity for up to 10 days after application of chlorhexidine
containing shampoos and rinses [30, 31]. The reasons for
the lack of persistent activity of the CHX wipes is unclear,
but may relate to the low concentration of chlorhexidine
in the formulation and further studies are indicated.
This study only used 10 clinical and one reference iso-
late of each organism for the in vitro experiment. Unfor-
tunately, a reference isolate for MRSP was not available
from NCTC at the time of this study. Ideally, larger
numbers of clinical isolates would have been studied.
However, the clinical isolates were chosen at random
across different time periods to maximize representative
sampling and avoid selection bias. The lack of bias is
also supported by the narrow range of the ZIs (most of
the 95% CI differed only 10% from the median results).
Furthermore, the results for the reference isolates sat
within the ranges established for the clinical isolates.
Wide variability in the results would have suggested that
much larger numbers of isolates would have been re-
quired to accurately demonstrate the relative in vitro
antimicrobial activity of these products.
The study design was chosen to reflect the activity of
the wipes rather than their ingredients, which have been
established and would be less clinically relevant to the
products as used. The experimental model was used to
provide data on comparative in vitro antimicrobial activ-
ity. However, it is important to note that the model does
not represent an in vitro disc diffusion test of the wipes
and the results must not be read as breakpoints implying
clinical susceptibility or resistance.
While these results demonstrate the in vitro anti-
microbial activity of the CHX, further studies are re-
quired to demonstrate clinical efficacy. This cannot be
assumed, as, for example, Boonyasiri and colleagues [37]
showed that there was no benefit to using 2% chlorhexi-
dine impregnated wash cloths versus non-antimicrobial
soap cloths for cleaning patients in a human ICU ward.
The median time to MDR bacterial colonisation was 5
days with no significant difference in hospitalisation time
or incidence of hospital acquired infections (including
ESBL-EC, Meticillin –resistant Staphylococcus aureus,
MDR Klebsiella pneumoniae and Acinetobacter bauma-
nii) [37]. Recent meta-analysis by Patel and colleagues
have found that there is no beneficial effect of daily use
of chlorhexidine containing products to prevent gram
negative bacterial infections caused by EC, PA, Acineto-
bacter, Klebsiella and Enterobacter [38].
Conclusion
This study has shown that CHX wipes inhibited the
in vitro growth of a range of pathogens relevant to
skin and wound infections in animals. AABA wipes
were ineffective in vitro. Growth of the MSSP, MRSP,
EC and MP isolates were inhibited, but the ESBL E.
coli isolates appeared to be less susceptible and all
the PA isolates achieved confluent growth. Clinicians
should therefore use clinical signs, cytology, and
where necessary culture, to determine whether treat-
ment of an infection with the CHX product is appro-
priate. Finally, there was no residual activity on the
hair suggesting that these CHX wipes need to be used
at least once a day on active infections. Further stud-
ies are, however, required to establish whether these
results can be replicated with larger samples and to
demonstrate in vivo clinical efficacy.
Methods
Microbial isolates
Ten isolates each of MRSP, MSSP, EC, ESBL-EC, PA and
MP were obtained from cases of canine otitis, pyoderma
and wound infections. These isolates were randomly s-
elected from samples submitted to the University of
Edinburgh Veterinary Pathology Unit microbiology labora-
tory for routine microbial culture and susceptibility testing.
Random numbers were computer generated to select sam-
ples using the laboratory submission numbers. Samples
with insufficient material, growth characteristics and/or
data were disregarded and the random selection process
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repeated until the target number was obtained. The organ-
isms were speciated and their antimicrobial susceptibility
established using standard methods employed by this accre-
dited laboratory using CLSI guidelines [39, 40]. Reference
isolates were obtained from the Public Health England
National Collection of Type Cultures (NCTC) and Public
Health England National Collection of Pathogenic Fungi
(NCPF). These were Staphylococcus pseudintermedius
NCTC 7151, E. coli NCTC 12241, CTX-M-15 ESBL E. coli
NCTC 13353, Pseudomonas aeruginosa NCTC 10662 and
Malassezia pachydermatis NCPF 3667. S. aureus EMRSA-
15 NCTC 13142 was used in the absence of an MRSP ref-
erence isolate. All the isolates were stored in tryptone soya
broth (bacteria) or Sabouraud dextrose broth (Malassezia)
with 15% glycerine at -80 °C until required. Isolates were
defrosted and cultured overnight on Columbia 5% horse
blood agar (bacteria) at 37 °C or for three days on Sabour-
aud dextrose agar (Malassezia) at 37 °C with 5% CO2.
Colonies were washed and diluted in sterile phosphate
buffered saline (PBS) to a visually assessed 0.5 McFarland
standard. All the media were obtained from Oxoid™
(ThermoFisher Scientific™, Basingstoke, UK).
Agar diffusion studies
The microbial isolates were spread onto Mueller-Hinton
(MH; bacteria) and Sabouraud dextrose (SD; Malassezia)
agar plates in a standard manner to achieve confluent
growth. 6 mm discs were cut using sterile instruments
from the chlorhexidine (CHX) and acetic acid/boric acid
(AABA) impregnated wipes, and negative controls (ster-
ile autoclaved Simple® Kind to Skin Facial Cleansing
Wipes [Unilever, Leatherhead, UK] and paper towel).
See Table 2 for further details of the composition of the
wipes. One disc of each was added to each plate. Anti-
microbial impregnated discs to which the isolate had
previously demonstrated susceptibility were used as
positive controls. The choice of antimicrobial was based
on previous culture and susceptibility testing performed
to accepted CLSI guidelines [39, 40]. These included:
30 μg cephalexin, 30 μg doxycycline, 10 μg gentamicin,
30 μg amoxicillin/clavulanic acid, 30 μg ceftazidime,
30 μg amikacin, 5 μg enrofloxacin and 25 μg fluconazole
(Oxoid™ ThermoFisher Scientific™, Basingstoke, UK). All
the plates were set up in duplicate. Negative control MH
and SD agar plates with the test, positive and negative
control discs but without microbial isolates, were also
included. Each isolate was incubated overnight (bacteria)
or for 3 days (Malassezia) at 37 °C and 5% CO2. The
plates were then examined for microbial growth and the
zones of inhibition (ZIs) were measured to the edge of
the microbial growth. Colony morphology and cyto-
logical examination were used to determine the purity of
the microbial growth.
In vivo residual activity study
Ethical approval through the parent institute was granted
for this part of the study and all owners gave informed
written consent. To evaluate the in vivo duration of activ-
ity, an area of haired skin on the lateral thorax in healthy
dogs was vigorously rubbed with the CHX (n = 5) or
AABA (n = 5) wipes until the hair and underlying skin was
thoroughly soaked. The other side of each dog was simi-
larly treated with sterile distilled water. Treatment alloca-
tion to CHX or AABA and to the right or left side was
randomly assigned using a coin toss with the investigator
blinded to the allocation. No further topical treatment or
grooming was permitted during the study period and the
dogs were kept dry. Hair samples were collected from the
treated sites at day 0 (i.e. before treatment), and then on
days 1 and 3. The hair was cut and weighed so that each
sample was the same size (1 cm length) and weight (0.1 g).
Plates with an MSSP, MRSP, EC, ESBL-EC and MP isolate
shown to be most susceptible to the CHX wipes were pre-
pared as above. The PA isolate was selected at random as
the isolates had all achieved confluent growth in the first
part of the study. Each plate was then inoculated with the
hair samples and positive control antimicrobial disc, and
incubated as above. The ZI around each hair sample was
examined and measured across the midpoint of the sam-
ple. Colony morphology and cytological examination were
used to determine the purity of the microbial growth.
Data analysis
The ZIs were recorded in mm. The median and 95%
confidence intervals (CIs) were calculated for the 11 iso-
lates of each organism. Kruskal-Wallis tests with post-
test analyses was used to compare the ZIs between the
test and control wipes for each microbial isolate (i.e.
CHX versus AABA for MSSP, MRSP, EC, ESBL-EC, PA
and MP) and then between the ZIs for each wipe among
the bacterial isolates (i.e. MSSP versus MRSP, EC, ESBL-
EC and PA for CHX and AABA). The MP isolates were
not included in the latter analysis as these used a differ-
ent culture methodology.
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